Exploring of greater yam (Dioscorea alata L.) genotypes through biochemical screening for better cultivation in south Gujarat zone of India.

Fifteen different genotypes of greater yam (Dioscorea alata) NGY-1, NGY-2, NGY-3, NGY-4, NGY-5, NGY-6, NGY-7, NGY-8, NGY-9, NGY-10, NGY-11, NGY-12, NGY-13, NGY-14 and Da-199 were procured from different places of south Gujarat, like Valsad, Navsari, Surat and Anand. Among the biochemical parameters total carbohydrate ranged between 51.87 and 87.85% from different genotypes, starch ranged from 47 to 80.67%, crude fat ranged from 0.6 to 2.32%, crude fibre ranged between 1.10 and 4.09%, anthocyanin content of genotypes ranged from 1.01 to 3.25 mg/g, beta-carotene content ranged between 0.97 and 1.88 µg/g. The antinutrients namely Diosgenin and Tannin ranged from 0.28 to 0.93% and 0.923 mg/100 g to 2.447 mg/100 g, respectively. RAPD analysis was also done by the help of 18 RAPD markers: OPA1, OPA2, OPA3, OPA13, OPB1, OPB6, OPB7, OPM1, OPM2, OPM4, OPM7, OPM11, OPM12, OPM13, OPM15, OPM16, OPM17 and OPM19 from which an average of 9.7 loci were detected with an average of 4.72 polymorphic loci which is 48.65% polymorphism per loci and 48.70% average polymorphism. From the overall study, it can be conferred that the study revealed highest carbohydrate content in NGY-3 (87.85%), fat (2.32%) and crude fiber content (4.09%) in NGY-11, ß-carotene in NGY-7 (1.88 µg/g), anthocyanin in NGY-4(3.25 mg/g). Lowest tannin (0.923 mg/100 g) and diosgenin (0.28%) was found in NGY-6, and NGY-7 respectively. For each of the biochemical parameters, the varieties with the optimum values may be cultivated. As the molecular studies revealed NGY-2 and NGY-3 have 96% similarities, they may be the duplicate of the same genotypes which can be studied further for better germplasm conservation.

Renal Transplant Acute Rejection with Lower Mycophenolate Mofetil Dosing and Proton Pump Inhibitors or Histamine-2 Receptor Antagonists.

BACKGROUND: Pharmacokinetic data show reduced mycophenolic acid levels in renal transplant recipients taking mycophenolate mofetil (MMF) and proton pump inhibitors (PPIs) concomitantly. This reduced exposure could increase rejection risk. The typical initial MMF dose post renal transplantation is 2 g/day, which often requires dose reduction secondary to side effects. Existing studies have not shown significant acute rejection differences for patients taking MMF-PPI versus patients taking MMF-ranitidine. OBJECTIVE: The purpose of this study was to evaluate clinical outcomes in renal transplant recipients receiving a lower MMF dose than previously studied (1.5 g/day) and either a PPI or histamine-2 receptor antagonist (H2RA). METHODS: This retrospective cohort study included adult subjects receiving a renal transplant between January 1, 2009, and June 30, 2013. Comparison groups were defined based on acid-suppressing therapy class prescribed at discharge from transplantation. The primary outcome was acute rejection incidence within 1 year posttransplantation. RESULTS: Of 728 renal transplant recipients screened, 522 were included: 183 taking a PPI and 339 taking an H2RA. There was no significant difference in acute rejection within 1 year (H2RA 19% versus PPI 14%, p=0.12) or 3 months (4% vs 5%, p=0.44, respectively) posttransplantation. Maintenance immunosuppression (MMF dose and tacrolimus troughs) was similar between groups at 3 months and 1 year. Graft and patient survivals were favorable (> 95%), and graft function at 1 year was stable and similar between groups. CONCLUSION: Despite taking lower MMF doses than previously studied, subjects on a PPI compared to an H2RA were not at increased risk of acute rejection within 1 year posttransplantation.

Single 4.5 mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome.

Rasburicase is a recombinant urate oxidase enzyme administered for treatment of hyperuricemia associated with tumor lysis syndrome. Studies demonstrate effectiveness of single fixed-dose rasburicase as compared to the FDA-approved dose of 0.2 mg/kg intravenously daily for up to five days. Doses in these studies range from 1.5 mg to 7.5 mg. Our study evaluated outcomes in patients who received single 4.5 mg fixed-dose rasburicase. This retrospective, IRB-approved chart review evaluated adult oncology subjects who received fixed-dose rasburicase between January 2007 and April 2014. The primary outcome was percentage of patients with normalization of uric acid (level <8 mg/dL within 24 h) after a single 4.5 mg fixed-dose of rasburicase. Secondary objectives were incidence of initial failure of fixed-dose rasburicase and normalization of uric acid in overweight (body mass index ≥25 kg/m2) versus non-overweight patients. Initial failure was defined as need for additional doses or progression to dialysis within one week of the initial fixed-dose. In the 128 patients included, the mean baseline uric acid level was 14.84 mg/dL. Of the 112 patients with a follow-up uric acid level, 68% achieved normalization within 24 h of rasburicase administration. Thirty-eight patients received additional treatment: 10 received additional dose(s) and 28 underwent dialysis. Normalization of uric acid in overweight versus non-overweight patients was 66% and 73%, respectively. Overall, a single 4.5 mg fixed-dose of rasburicase effectively normalized uric acid in 68% of patients within 24 h. Further studies are needed to determine the optimal single fixed-dose necessary for treatment response across all patients.